Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1677 | 2017 |
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ... Nature genetics 46 (3), 225-233, 2014 | 1356 | 2014 |
Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1156 | 2017 |
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 537 | 2018 |
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 413 | 2017 |
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study SM Domchek, S Postel-Vinay, SA Im, YH Park, JP Delord, A Italiano, ... The Lancet Oncology 21 (9), 1155-1164, 2020 | 330 | 2020 |
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study DG Rothwell, M Ayub, N Cook, F Thistlethwaite, L Carter, E Dean, N Smith, ... Nature medicine 25 (5), 738-743, 2019 | 237 | 2019 |
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair N Kanu, E Grönroos, P Martinez, RA Burrell, X Yi Goh, J Bartkova, ... Oncogene 34 (46), 5699-5708, 2015 | 184 | 2015 |
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers S Gulati, P Martinez, T Joshi, NJ Birkbak, CR Santos, AJ Rowan, ... European urology 66 (5), 936-948, 2014 | 172 | 2014 |
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse F Chemi, DG Rothwell, N McGranahan, S Gulati, C Abbosh, SP Pearce, ... Nature medicine 25 (10), 1534-1539, 2019 | 171 | 2019 |
The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer A Lallo, KK Frese, CJ Morrow, R Sloane, S Gulati, MW Schenk, F Trapani, ... Clinical Cancer Research 24 (20), 5153-5164, 2018 | 146 | 2018 |
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution R Fisher, S Horswell, A Rowan, MP Salm, EC de Bruin, S Gulati, ... Genome biology 15, 1-15, 2014 | 87 | 2014 |
Understanding cancer mechanisms through network dynamics TMK Cheng, S Gulati, R Agius, PA Bates Briefings in functional genomics 11 (6), 543-560, 2012 | 47 | 2012 |
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer S Mohan, M Ayub, DG Rothwell, S Gulati, B Kilerci, A Hollebecque, ... Scientific reports 9 (1), 11610, 2019 | 45 | 2019 |
Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics A Lallo, S Gulati, MW Schenk, G Khandelwal, UW Berglund, IS Pateras, ... British journal of pharmacology 176 (3), 436-450, 2019 | 40 | 2019 |
Cancer networks and beyond: interpreting mutations using the human interactome and protein structure S Gulati, TMK Cheng, PA Bates Seminars in cancer biology 23 (4), 219-226, 2013 | 27 | 2013 |
In vitro antimicrobial activity of ethanolic extract of Aloe vera against some bacterial and fungal species P Prashar, S Gulati, V Koul, S Sehgal, S Sehgal Adv Bio Tech 11 (3), 32-33, 2011 | 13 | 2011 |
Relapse models for clear cell renal carcinoma S Gulati, S Turajlic, J Larkin, PA Bates, C Swanton The Lancet Oncology 16 (8), e376-e378, 2015 | 5 | 2015 |
Publisher correction: pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse F Chemi, DG Rothwell, N McGranahan, S Gulati, C Abbosh, SP Pearce, ... Nature medicine 26 (7), 1147-1147, 2020 | 3 | 2020 |
clear cell Renal Cell Carcinoma: Biomarkers and Networks S Gulati UCL (University College London), 2016 | 2 | 2016 |